Summary
Garlic (Allium sativum) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Hypertension. ClinicalTrials.gov lists 1 registered trial linking Garlic (Allium sativum) to Hypertension: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 25 participants. Registered activity dates to 2025. The literature layer holds 3 publications for this pair: 2 Cochrane reviews and 1 clinical trial publication. Publication years run from 2007 to 2023. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 20.0 (trials 3.0, literature 12.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 1 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (2 Cochrane reviews, 1 clinical trial publication) |
| Agent type | Supplement (Herbal) |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Herbal antihypertensive interventions: a narrative review · Halma M, et al. · 2024 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05067998 | The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature 2025 | recruiting | Not applicable | 25 |
Published literature
- Clinical trial publication Antihypertensive Effects of an Optimized Aged Garlic Extract in Subjects with Grade I Hypertension and Antihypertensive Drug Therapy: A Randomized, Triple-Blind Controlled TrialSerrano JCE, Castro-Boqué E, García-Carrasco A et al. · Nutrients · 2023 · PMID 37686723
- Cochrane review Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysisReinhart KM, Coleman CI, Teevan C et al. · The Annals of pharmacotherapy · 2008 · PMID 19017826
- Cochrane review Clinical effectiveness of garlic (Allium sativum)Pittler MH, Ernst E · Molecular nutrition & food research · 2007 · PMID 17918163
Mechanism and notes
Recorded mechanism or class: Herbal antihypertensive interventions: a narrative review · Halma M, et al. · 2024.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Garlic (Allium sativum) approved for Hypertension?
Garlic (Allium sativum) has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Garlic (Allium sativum) in clinical trials for Hypertension?
ClinicalTrials.gov lists 1 registered trial linking Garlic (Allium sativum) to Hypertension: 1 is currently recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 25 participants. Registered activity dates to 2025.
What does the evidence show for Garlic (Allium sativum) in Hypertension?
Trials of Garlic (Allium sativum) in Hypertension are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.